Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors

2 Jun 2016

Abstract excerpt

Abstract Purpose: To identify novel mechanisms of resistance to third-generation EGFR inhibitors in patients with lung adenocarcinoma that progressed under therapy with either AZD9291 or rociletinib (CO-1686). Experimental Design: We analyzed tumor biopsies from seven patients obtained before, during, and/or after treatment with AZD9291 or rociletinib (CO-1686). Targeted sequencing and FISH analyses were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer therapeutics and mechanisms
Share to Colorectal Cancer Treatments and Studies
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27252416
DOI: 10.1158/1078-0432.ccr-15-1915

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR InhibitorsPMID 27252416Read ↗

Novel Third-Generation EGFR Tyrosine Kinase Inhibitors and Strategies to Overcome Therapeutic Resistance in Lung CancerSemantic proximity Read ↗

Strategies Beyond 3rd EGFR‐TKI Acquired Resistance: Opportunities and ChallengesSemantic proximity Read ↗

Putative mechanisms of primary resistance to EGFR-targeted therapies: A retrospective study.Semantic proximity Read ↗

Mechanisms of Acquired Resistance to AZD9291: A Mutation-Selective, Irreversible EGFR Inhibitor.Semantic proximity Read ↗

Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors.Semantic proximity Read ↗

Strategies for overcoming EGFR resistance in the treatment of advanced-stage NSCLC.Semantic proximity Read ↗

Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study.Semantic proximity Read ↗

Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.Semantic proximity Read ↗

Genomic and Molecular Screenings Identify Different Mechanisms for Acquired Resistance to MET Inhibitors in Lung Cancer Cells.Semantic proximity Read ↗

Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer.Semantic proximity Read ↗

Potential Resistance Mechanisms Revealed by Targeted Sequencing from Lung Adenocarcinoma Patients with Primary Resistance to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs)Semantic proximity Read ↗

Emerging strategies to overcome resistance to third-generation EGFR inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.